Adjuvant radiotherapy is often recommended after modified radical mastectomy in breast carcinoma patients to reduce the risk of local and regional recurrence. The decision is typically based on factors indicating a higher risk of recurrence.
Adjuvant radiotherapy is generally indicated in cases with:
Oestrogen receptor (ER) and Progesterone receptor (PR) status primarily guides the decision for systemic endocrine (hormonal) therapy, especially for ER/PR positive tumours. While ER/PR negative tumours can sometimes be more aggressive systemically, their status alone is not a primary indication for adjuvant radiotherapy after mastectomy when compared to local factors like tumour size, margin status, and lymph node burden. Radiotherapy focuses on controlling local and regional disease.
Based on the established criteria for adjuvant radiotherapy post-mastectomy:
The clinical scenario where adjuvant radiotherapy is generally *not* indicated solely based on the provided options is when the tumour is ER, PR hormone receptor negative, assuming other high-risk factors (size, margins, nodes) are not present or are managed differently.